Fig. 4From: Evaluation of the expression levels of BRAFV600E mRNA in primary tumors of thyroid cancer using an ultrasensitive mutation assayDetection of the BRAFV600E mutation in FFPE samples using DNA sequencing. Sanger DNA sequencing was used as a reference method to detect the BRAFV600E mutation in clinical FFPE specimens from patients with thyroid cancer and non-malignant thyroid disease. a Sequencing chromatogram showing two peaks (red and green) at the nucleotide position of interest for a sample with the BRAFV600E mutation (B7020), and b single peak (red) for a sample with wild type BRAF only (B6659)Back to article page